Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC)

Date

09 Oct 2016

Session

Poster display

Presenters

Andrea Necchi

Citation

Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373

Authors

A. Necchi1, G. Sonpavde2, S. Lo Vullo3, A. Bamias4, S.J. Crabb5, L. Harshman6, J. Bellmunt7, U. De Giorgi8, C. Sternberg9, S. Ladoire10, Y. Wong11, E.Y. Yu12, S. Chowdhury13, G. Niegisch14, S. Srinivas15, U. Vaishampayan16, S.K. Pal17, J. Rosenberg18, L. Mariani3, M.D. Galsky19

Author affiliations

  • 1 Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Medical Oncology, University of Alabama at Birmingham Hospital, 35294-3280 - Birmingham/US
  • 3 Clinical Epidemiology And Trials Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 4 Clinical Therapeutics, University of Athens, 115 28 - Athens/GR
  • 5 Medical Oncology, University of Southampton, Southampton/GB
  • 6 Medical Oncology, Dana-Farber Cancer Institute, Boston/US
  • 7 Bladder Cancer Center, Dana-Farber Cancer Institute, Boston, MA/US
  • 8 Medical Oncology, Istituto Tumori della Romagna I.R.S.T., Meldola/IT
  • 9 Oncology, San Camillo–Forlanini Hospital, 00152 - Rome/IT
  • 10 Medical Oncology, Centre Georges-François Leclerc (Dijon), Dijon/FR
  • 11 Medical Oncology, Fox Chase Cancer Center, Philadelphia/US
  • 12 Medical Oncology, Univ. Washington/VAPSHCS, Seattle/US
  • 13 Oncology, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB
  • 14 Medical Oncology, Univesitätsklinikum Düsseldorf, Düsseldorf/DE
  • 15 Medical Oncology, Stanford University Medical Center, Stanford/US
  • 16 Medical Oncology, Karmanos Cancer Institute, Detroit/US
  • 17 Medical Oncology And Experimental Therapuetics, City of Hope, 91010 - Duarte/US
  • 18 Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 19 Tisch Cancer Institute, Mount Sinai School of Medicine, New York/US
More

Resources

Abstract 2322

Background

The available prognostic models of OS for pts with metastatic UC were derived from clinical trial populations of cisplatin-treated pts only. We aimed to develop a new model based on ‘real world’ pts.

Methods

Individual pt-level data from 29 centers was collected. Pts had to be treated for metastatic UC at the participating sites between 01/2006 and 01/2011. Selection criteria included metastatic UC, and first-line cisplatin- or carboplatin-based chemotherapy. The overall sample was randomly split into a development and a validation cohort. Generalized Boosted Regression Modeling was used first to exclude variables not associated with OS. Backward variable selection was then undertaken. Platinum-type was incorporated in the analysis as a stratification factor. Two nomograms were built to estimate OS probability, the first based on baseline factors and the second incorporating objective response (OR). The performance of the present nomogram and that of the other available models was assessed for accuracy (Brier score), calibration (Hosmer-Lemeshow test), and discrimination (Harrell c-index).

Results

1,020 pts were analyzed (development: 687; validation: 333). In the platinum-stratified Cox model, significant variables for OS were: performance status (p 

Conclusions

We developed and validated two nomograms that accounted for novel prognostic factors and can be used before and after completion of chemotherapy, respectively. These two nomograms may be suitable tools to enhance patient stratification and inform pts in the clinic.

Clinical trial identification

None

Legal entity responsible for the study

Fondazione IRCCS Istituto Nazionale dei Tumori

Funding

Fondazione IRCCS Istituto Nazionale dei Tumori

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings